CNS pen. GPR6 GPCR inverse agonist oral QD Ph. II candidate for Parkinson's from 360k cmpd cell-based HTS + opt. J. Pharmacol. Exp. Ther., Apr. 1, 2021 Cerevance / Takeda California, San Diego, US